Breast Cancer Clinical Trial

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Summary

The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.

View Full Description

Full Description

The study is designed as a prospective, single-arm, nonrandomized, open-label, phase I/II trial of radiation therapy (RT) followed by intrathecal (IT) trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease (LMD). Treatment will be initiated with RT, whole brain RT (WBRT) and/or focal brain/spine RT followed by IT trastuzumab/pertuzumab.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmation of HER2 positivity. All patients with HER2+ cancers will be allowed to enroll if they have leptomeningeal disease (LMD). Patients may be IHC 3+ and/or FISH-positive. IHC 2+ HER2 patients are eligible with reflex FISH-positive testing with the ratio ≥2.0
Participants may have concomitant brain metastases
Cerebrospinal fluid (CSF) sampling is required to document LMD if not documented by MRI. Participants are still eligible CSF is negative but LMD disease is documented on MRI
Life expectancy greater than 8 weeks
Consent to pretreatment tumor biopsy or retrieval of archival tissue
Normal renal (creatinine <1.5 × upper limit of normal [ULN]), liver (bilirubin < 1.5 × ULN, transaminases <3.0 × ULN, except in known hepatic disease, wherein may be <5 × ULN) and blood counts (white cells ≥2.5, neutrophils ≥1000, platelets ≥75,000, hemoglobin ≥8)
LVEF >50%
KPS >/= 60
Patients with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon
There is no limit on prior systemic or IT therapies
Must be willing to have an Ommaya reservoir placed and a candidate for an Ommaya reservoir placement
Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study. Contraception methods should start a minimum of 14 days before the first administration of study drug and continue for the duration of study treatment and for at least 7 months after the last dose of study treatment.
Ability to sign informed consent.
Patients may continue treatment with IV trastuzumab, pertuzumab, or other HER2-directed, hormonal, or chemotherapeutic agents if controlling systemic disease and leptomeningeal metastases that developed while on these therapies. In addition, at time of systemic progression, patients may start additional agents at the discretion of the treating physician according to criteria per protocol.

Exclusion Criteria:

Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of the first dose of study treatment
Cannot be on systemic agents (chemotherapy) that have Central Nervous System (CNS) penetration (temozolomide, carmustine, lomustine, etoposide, capecitabine, carboplatin, vinorelbine, bevacizumab, irinotecan, and topotecan) unless they develop or have progressive or persistent leptomeningeal metastases while on these agent(s). See protocol for additional information regarding systemic therapies.
Major surgery or significant traumatic injury that has not been recovered from 14 days before the initiation of study drug
Symptomatic lung disease resulting in shortness of breath at rest
Women who are pregnant or breastfeeding
History of serious adverse event to any of the study drugs or study drug components
Whole Body Radiation Therapy (WBRT) is not allowed while patients receive IT trastuzumab/pertuzumab; however, focal stereotactic or palliative RT is allowed
Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

39

Study ID:

NCT04588545

Recruitment Status:

Recruiting

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Moffitt Cancer Center
Tampa Florida, 33612, United States More Info
Michelle DeJesus
Contact
813-745-6911
[email protected]
Kamran Ahmed, MD
Principal Investigator
Peter Forsyth, MD
Principal Investigator
Avan Armaghani, MD
Sub-Investigator
Ricardo Costa, MD, MSc
Sub-Investigator
Arnold Etame, MD, PhD
Sub-Investigator
Heather Han, MD
Sub-Investigator
Hung Khong, MD
Sub-Investigator
James Liu, MD
Sub-Investigator
Loretta Loftus, MD, MBA
Sub-Investigator
Sepideh Mokhtari, MD
Sub-Investigator
Solmaz Sahebjam, MD
Sub-Investigator
Hatem Soliman, MD
Sub-Investigator
Nam Tran, MD, PhD
Sub-Investigator
Michael Votgelbaum, MD, PhD
Sub-Investigator
Michael Yu, MD
Sub-Investigator
Northwestern University
Evanston Illinois, 60208, United States More Info
Priya Kumthekar, MD
Contact
312-695-4360
[email protected]
Priya Kumthekar, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

39

Study ID:

NCT04588545

Recruitment Status:

Recruiting

Sponsor:


H. Lee Moffitt Cancer Center and Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.